NO20073764L - Sammensetninger for behandling av HCV - Google Patents

Sammensetninger for behandling av HCV

Info

Publication number
NO20073764L
NO20073764L NO20073764A NO20073764A NO20073764L NO 20073764 L NO20073764 L NO 20073764L NO 20073764 A NO20073764 A NO 20073764A NO 20073764 A NO20073764 A NO 20073764A NO 20073764 L NO20073764 L NO 20073764L
Authority
NO
Norway
Prior art keywords
hcv
compositions
treatment
agent
compound
Prior art date
Application number
NO20073764A
Other languages
English (en)
Norwegian (no)
Inventor
Kai Lin
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073764L publication Critical patent/NO20073764L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20073764A 2004-12-23 2007-07-19 Sammensetninger for behandling av HCV NO20073764L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867504P 2004-12-23 2004-12-23
PCT/US2005/046059 WO2006071619A1 (fr) 2004-12-23 2005-12-20 Compositions pour le traitement du vhc

Publications (1)

Publication Number Publication Date
NO20073764L true NO20073764L (no) 2007-09-18

Family

ID=36155247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073764A NO20073764L (no) 2004-12-23 2007-07-19 Sammensetninger for behandling av HCV

Country Status (16)

Country Link
US (1) US7897565B2 (fr)
EP (1) EP1830871A1 (fr)
JP (1) JP2008525459A (fr)
KR (1) KR20070087624A (fr)
CN (1) CN101076350A (fr)
AU (1) AU2005322242B2 (fr)
BR (1) BRPI0519345A2 (fr)
CA (1) CA2587793A1 (fr)
IL (1) IL183659A0 (fr)
MA (1) MA29098B1 (fr)
MX (1) MX2007007779A (fr)
NO (1) NO20073764L (fr)
NZ (1) NZ555143A (fr)
RU (1) RU2007128099A (fr)
WO (1) WO2006071619A1 (fr)
ZA (1) ZA200703908B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7671017B2 (en) 2004-07-14 2010-03-02 Novartis Ag Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
AU2005322241B2 (en) * 2004-12-23 2010-02-18 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc
AU2006259348B2 (en) * 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
EP1909564A4 (fr) * 2005-07-18 2010-06-30 Novartis Ag Modele petit animal pour une replication hcv
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (fr) 2005-09-30 2011-02-16 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
EP2023918B1 (fr) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporines pour le traitement et la prévention de troubles oculaires
CA2665415A1 (fr) * 2006-10-12 2008-04-17 Novartis Ag Utilisation de cyclosporines modifiees
WO2008069917A2 (fr) 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
EP2376524B1 (fr) 2008-12-31 2017-03-15 Cypralis Limited Dérivés de cyclosporine a
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
PH12012501216A1 (en) * 2009-12-18 2012-11-05 Boehringer Ingelheim Int Hcv combination therapy
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
CA2818067A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Nouveaux traitements de l'infection par le virus de l'hepatite c
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
AU2012233644A1 (en) 2011-03-31 2013-09-12 Novartis Ag Alisporivir to treat Hepatitis C virus infection
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN103648516A (zh) 2011-04-13 2014-03-19 诺华股份有限公司 使用阿拉泊韦治疗丙型肝炎病毒感染
RU2014116988A (ru) 2011-09-27 2015-11-10 Новартис Аг Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
WO2015017382A1 (fr) * 2013-07-29 2015-02-05 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3454856B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU2001295966A1 (en) * 2000-10-19 2002-04-29 Fujisawa Pharmaceutical Co. Ltd. Cell damage inhibitor
AR036081A1 (es) * 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CN1753687A (zh) * 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
WO2006071619A1 (fr) 2004-12-23 2006-07-06 Novartis Ag Compositions pour le traitement du vhc

Also Published As

Publication number Publication date
US20090104149A1 (en) 2009-04-23
AU2005322242B2 (en) 2010-02-11
AU2005322242A1 (en) 2006-07-06
ZA200703908B (en) 2009-06-24
MA29098B1 (fr) 2007-12-03
BRPI0519345A2 (pt) 2009-01-20
EP1830871A1 (fr) 2007-09-12
KR20070087624A (ko) 2007-08-28
JP2008525459A (ja) 2008-07-17
CN101076350A (zh) 2007-11-21
NZ555143A (en) 2009-12-24
IL183659A0 (en) 2007-09-20
CA2587793A1 (fr) 2006-07-06
US7897565B2 (en) 2011-03-01
MX2007007779A (es) 2007-08-14
WO2006071619A1 (fr) 2006-07-06
RU2007128099A (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
NO20073764L (no) Sammensetninger for behandling av HCV
NO20092053L (no) HCV NS3-proteaseinhibitorer
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091704L (no) Inhibitorer av hepatitt C virus
NO20091707L (no) Inhibitorer av hepatitt C virus
EP1802650A4 (fr) Derives de cyclosporine 3-ether et 3-thioether substitues utilises dans le traitement et la prevention d'une infection par hepatite c
NO20073765L (no) Forbindelser for behandling av flaviviridae
ATE433447T1 (de) Pyrimiidinverbindungen
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20091706L (no) Inhibitorer av hepatitt C virus
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
GB0612423D0 (en) Therapeutic agents
NO20081844L (no) Terapeutiske forbindelser
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
EA200801997A1 (ru) Новые соединения
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
TW200626585A (en) 18-membered macrocycles and analogs thereof
SE0303480D0 (sv) Benzofuranes
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application